GLP-1s account for 8% of all US prescriptions GLP-1 RA prescribing has reached a new milestone, with nearly 8% of all prescriptions in March 2026 attributed to these therapies following the largest quarter-over-quarter percentage point increase in overall GLP-1 RA prescribing observed since the study began in 2019
Dermatol 60, 166173
What We Teach Our Clients to Rebuild We dont just say eat more protein. We walk you through the whole process: How to recognize emotional hunger vs physical hunger How to rebuild a daily structure that supports your metabolism What to eat when youre not hungry but still need energy How to rewrite your identity from I always quit to I always reset And how to make choices on purpose , not just on autopilot You dont have to be perfect
Cortisone injections provide temporary relief while potentially weakening tissue over time
GIP Receptor Activation: augmenting insulin response to meals and further throttling appetite mirrors a broader weight control strategy, outlining differences like Mounjaro vs Zepbound and elucidating their combined potential
Those who shouldnt take GLP-1 agonists include people who: are pregnant, nursing, or planning to become pregnant have a history of thyroid cancer or pancreatitis are allergic or sensitive to any of the GLP-1 medications have multiple endocrine neoplasia (MEN) syndrome type 2 Weight loss medications are not recommended for people with past or active eating disorders